6 new oncology trials approved in Europe
 |
Oncology Hero |
6 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week.
Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high
| Sponsor: UZ Brussel | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestRandomized study evaluating the impact of an innovative and cooperative pathway integrating OncoGeriatric, pharmaceutical and Pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy. (POG)
| Sponsor: Institut Gustave Roussy | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
| Sponsor: Amgen Inc. | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
| Sponsor: Bristol-Myers Squibb Services Unlimited Company | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestZoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma (ZAPGIO)
| Sponsor: Region Nordjylland | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestRandomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
| Sponsor: Ribocure Pharmaceuticals AB | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestOncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients Sponsor: Centre Leon Berard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest PD-1 blockade alone versus...
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial. Sponsor: Consorci Mar Parc De Salut De Barcelona Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest A phase 2 study to assess efficacy of induction...
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study. Sponsor: Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest [18F] MC225 PET...